AbCellera Biologics (ABCL) Net Income towards Common Stockholders (2020 - 2023)
AbCellera Biologics' Net Income towards Common Stockholders history spans 4 years, with the latest figure at -$47.2 million for Q4 2023.
- For the quarter ending Q4 2023, Net Income towards Common Stockholders fell 57.73% year-over-year to -$47.2 million, compared with a TTM value of -$47.2 million through Sep 2024, up 63.49%, and an annual FY2024 reading of -$162.9 million, down 11.24% over the prior year.
- Net Income towards Common Stockholders for Q4 2023 was -$47.2 million at AbCellera Biologics, down from -$28.6 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $168.6 million in Q1 2022, with the low at -$47.2 million in Q4 2023.
- Average Net Income towards Common Stockholders over 4 years is $17.8 million, with a median of -$2.5 million recorded in 2020.
- Biggest YoY gain for Net Income towards Common Stockholders was 5700.62% in 2021; the steepest drop was 693.91% in 2021.
- Tracing ABCL's Net Income towards Common Stockholders over 4 years: stood at $117.0 million in 2020, then tumbled by 48.76% to $59.9 million in 2021, then plummeted by 149.86% to -$29.9 million in 2022, then plummeted by 57.73% to -$47.2 million in 2023.
- Per Business Quant, the three most recent readings for ABCL's Net Income towards Common Stockholders are -$47.2 million (Q4 2023), -$28.6 million (Q3 2023), and -$30.5 million (Q2 2023).